ReviewOncotarget2017
Current diagnostics and treatment of fibrosarcoma -perspectives for future therapeutic targets and strategies.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 139 citations in OpenAlex.
- Hotspots and future trends of dermatofibrosarcoma protuberans.Frontiers in oncology · 2024Pooled it
- Gene Expression Profiling ofJournal of clinical practice and research · 2026Article
- The Added Value of Plastic Surgery in the Multidisciplinary Management of Sarcoma Resection: A Multivariable Analysis of Predictors and Postoperative Outcomes.Annals of surgical oncology · 2026Article
- Biomimetic dual-driven STING nanoagonist orchestrates neoadjuvant mild photo-immunotherapy for fibrosarcoma.Materials today. Bio · 2026Article
- New Insight in Pediatric Orthopedic Oncology: The Use of a Xeno-Hybrid Bone Substitute in Loss of Bone Tissue After Oncological Resections, a Case Series.Journal of clinical medicine · 2026Article
- Sinonasal Sarcomas Management: An International Consensus Statement.International forum of allergy & rhinology · 2026Article
- Multifaceted anticancer activity of nafamostat mesylate in human fibrosarcoma: first evidence of mitochondrial apoptosis and suppressed MMP-2/-9 mRNA expression.BMC pharmacology & toxicology · 2025Article
- Dermatofibrosarcoma Protuberans (DFSP): Diagnostics and Molecular Pathology.Current treatment options in oncology · 2025Review
- A Rare Case of Progressive and Invasive Adult Fibrosarcoma: Retroperitoneal Tumour Involving the Duodenum.Cureus · 2025Article
- Epigenetic paradigm of DNA methylation for understanding the pathophysiology, diagnostics, and therapeutics in sarcomas.Epigenomics · 2025Review
- AMPK Limits MNNG-Induced Parthanatos by Inhibiting BH3-Only Protein Bim.International journal of molecular sciences · 2025Article
- The Effect of Lurbinectedin as a Monotherapy and in Combination with Ionizing Radiation on Sarcoma Cell Lines.Cancers · 2025Article
- Histological and Immunohistochemical Findings of an Extremely Rare Multi-Organ Metastasis of Fibrosarcoma in a Holstein Cow.Veterinary medicine and science · 2025Article
- Article
- Not only vascular lesions: a case report of infantile fibrosarcoma.Journal of ultrasound · 2025Article
- Implementation of a CAM Assay Using Fibrosarcoma Spheroids.International journal of molecular sciences · 2025Article
- Fibrosarcoma of the maxilla with maxillary sinus invasion: a case report and review of the literature.Journal of medical case reports · 2025Review
- Article
- Case Report: Bowel obstruction caused by an adult fibrosarcoma located in the pelvis.Frontiers in surgery · 2025Article
- The proliferation rates of HT-1080 human fibrosarcoma cells can be accelerated or inhibited by weak static and extremely low frequency magnetic fields.Frontiers in public health · 2025Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult-type fibrosarcoma is a rare and highly aggressive subtype of soft tissue sarcomas. Due to the existence of other spindle-cell shaped sarcomas, its diagnosis is always one of exclusion. The likelihood of misdiagnoses between similar tumour entities is high, and often leads to inappropriate tumour treatment. We summarize here the main features of fibrosarcoma. When fibrosarcoma is appropriately diagnosed, the patient`s overall prognosis is generally quite poor. Fibrosarcoma is characterized by its low sensitivity towards radio- and chemotherapy as well as by its high rate of tumour recurrences. Thus it is important to identify new methods to improve treatment of this tumour entity. We discuss some promising new directions in fibrosarcoma research, specifically focusing on more effective targeting of the tumour microenvironment. Communication between tumour cells and their surrounding stromal tissue play a crucial role in cancer progression, invasion, metastasis and chemosensitivity. The therapeutic potential of targeting the tumour microenvironment is addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.